Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Use of MSCs to promote engraftment in large animal models

From: Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation

HSC source Model Conditioning; Immune suppression MSC source MSC dose Outcome Ref
Human CD34+BM cells Fetal sheep xenograft None; n/a Human autologous & allogeneic BM 5 × 104 - 7.5 × 105 Increased engraftment in PB and BM, no difference between autologous & allogeneic 16
Haploidentical BM cells Canine 9.2 Gy; n/a Allogeneic BM (3rd party), immortalized clonal populations or primary MSC culture 3 dosing schedules: 30 × 106/kg 3×/wk ×1 wk, then 2×/wk; 15 × 106/kg 5×/wk; 1 × 106/kg 3×/wk No effect; 50 % graft rejection & 50 % fatal acute GVHD 26
DLA-identical BM cells Canine 1 Gy; MMF and CSA Donor-derived BM 1.2 - 1.8 × 106/kg day 0, 1.1 - 1.3 × 106/kg day 35 No effect, uniform graft rejection at median of 8 weeks after initial donor engraftment 27
Autologous CD34+ BM cells (intra-BM) Nonhuman primate 5.5 Gy ×2 doses or Bu; n/a Autologous BM NR 1.6-6 fold increase in donor CFUs in BM 28
  1. MSCs indicates mesechymal stromal cells, HSC hematopoietic stem cells, BM bone marrow, PB peripheral blood, Gy gray, Bu busulfan, NR not reported, CFUs colony-forming units, wk week, GVHD graft-versus-host disease, DLA dog leukocyte antigen, MMF mycophenolate mofetil, CSA cyclosporine